GlassScriptPhysician profile
Dalandra Cavada Belcher
NPI 1285031245
$8,096.82
in general payments reported to CMS, 2019-2025
24 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,788 · 2022: $1,017 · 2023: $830 · 2024: $3,236 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,217 · Travel and Lodging: $1,030 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,217.18 |
| Travel and Lodging | $1,030.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,022.86 | 2022-2025 | Intellis Adaptivestim, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,983.15 | 2021-2025 | Relistor |
| Redhill Biopharma INC. | $709.26 | 2021 | |
| Curonix LLC | $416.58 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Foundation Fusion Solutions, LLC | $359.59 | 2024-2025 | |
| Forte Bio-Pharma LLC | $225.88 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Grt US Holding, INC. | $170.83 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $151.58 | 2021-2023 | Belbuca |
| Stryker Corporation | $150.00 | 2024 | Mild Device Kit |
| Nalu Medical, INC. | $142.88 | 2022 | |
| Spinal Simplicity, LLC | $142.88 | 2025 | Ha Minuteman G3-R |
| Vertos Medical, INC. | $139.53 | 2024 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $85.83 | 2021-2024 | |
| Horizon Therapeutics Plc | $76.36 | 2021-2022 | |
| Uswm, LLC | $60.17 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $59.67 | 2021 | |
| Almatica Pharma LLC | $41.03 | 2021 | |
| Biodelivery Sciences International, INC. | $39.73 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.17 | 2024 | |
| Bioventus LLC | $21.78 | 2022 | |
| Amgen INC. | $20.99 | 2021 | |
| Merz Pharmaceuticals, LLC | $15.67 | 2024 | Xeomin |
| Pfizer INC. | $15.22 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.18 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalandra Belcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.